The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

Drug Metabolism and Disposition

Volumn 31, Issue 7, 2003, Pages 815-832

  Bjornsson, Thorir D ^l   Callaghan, John T ^g   Einolf, Heidi J ^k   Fischer, Volker ^k   Gan, Lawrence ^j   Grimm, Scott ^c   Kao, John ^l   King, S Peter ^d   Miwa, Gerald ^j   Ni, Lan ^g   Kumar, Gondi ^b   McLeod, James ^k   Obach, R Scott ^l   Roberts, Stanley ^a   Roe, Amy ^m   Shah, Anita ^e   Snikeris, Fred ⁿ   Sullivan, John T ^b   Tweedie, Donald ^f   Vega, Jose M ⁱ   Walsh, John ^h   Wrighton, Steven A ^g   more..

^a ABBOTT LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c ASTRAZENECA   (United Kingdom)

^d SANOFI   (France)

^e BAYER CORPORATION   (United States)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j MILLENNIUM PHARMACEUTICALS INC   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

^l PFIZER INC   (United States)

^m PROCTER AND GAMBLE COMPANY   (United States)

ⁿ Sanofi Syntelabo   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZITHROMYCIN; BETA NAPHTHOFLAVONE; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRUG METABOLIZING ENZYME; ENZYME INDUCING AGENT; ERYTHROMYCIN; FEXOFENADINE; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; LOPERAMIDE; OMEPRAZOLE; PACLITAXEL; PENICILLIN DERIVATIVE; PHENOBARBITAL; PROBENECID; PROCAINAMIDE; QUINIDINE; RIFAMPICIN; TALINOLOL; UNINDEXED DRUG; VALSPODAR; VERAPAMIL;

ANIMAL CELL; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG SULFATION; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INDUSTRY; DRUG INTERACTIONS; RESEARCH DESIGN;

ANIMALIA;

EID: 10744232330     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.7.815     Document Type: Review

References (97)

1. Adedoyin A, Frye RF, Mauro K, and Branch RA (1998a) Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 46:215-219.
2. Adedoyin A, Stiff DD. Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, and Trump DL (1998b) All-traits-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 41:133-139.
3. Ahonen J, Olkkola KT, and Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharinacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270-272.
4. Ahonen J, Olkkola KT, and Neuvonen PJ (1997) Effect of route of administration of fluconazole on the interaction between flucoiiazole and midazolam. Eur J Clin Pharmacol 51:415-419.
5. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926.
6. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, and Thakker DR (1993) Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun 197:360-365.
7. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
8. Backman JT, Aranko K, Himberg JJ, and Olkkola KT (1994a) A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 46:551-555.
9. Backman JT, Kivisto KT. Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Ear J Clin Pharmacol 54:53-58.
10. Backman JT. Olkkola KT. Aranko K. Himberg JJ, and Neuvonen PJ (1994b) Dose of midazolain should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
11. Backman JT, Olkkola KT, and Neuvonen PJ (1995) Azithromycin does not increase plasma concentrations of oral midazolam, Int J Clin Pharmacol Ther 33:356-359.
12. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
13. Blum RA, Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Stepanavage M, Wilson MF, and Vega JM (1999) The effect of grapefruit juice (GFJ) on plasma levels of simvastatin HMG-CoA reductase inhibitors. 71st Congress of the European Atherosclerosis Society, May 28-29, Athens, Greece.
14. Boulton DW and Fawcett JP (2001) The pharmacokinetics of levosalbutamol: what are the clinical implications? Clin Pharmacokinet 40:23-40.
15. Branch RA, Adedoyin A, Frye RF, Wilson JW, and Romkes M (2000) In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 68:401-411.
16. Bretschneider B. Brandsch M. and Neubert R (1999) Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1) the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 16:55-61.
17. Brockmoller J and Roots J (1994) Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 27:216-248.
18. Burger DM, Meenhorst PL, Koks CH, and Beijnen JH (1993) Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 37:1426-1431.
19. Chang M, Dahl ML, Tybring G, Gotharson E, and Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2CI phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2CI9 genotype. Pharmacogenetics 5:358-363.
20. Chiou WL, Chung SM, Wu TC, and Ma C (2001) A comprehensive accounton on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 39:93-101.
21. Choc MG, Mueller EA, Robinson WT, Kumle A, Smith HT, and Charnick SB (1998) Relative bioavailability of Neoral versus Sandimmune in the presence of a P450111A and P-glycoprotein inhibitor. Transplant Proc 30:1664-1665.
22. Christians U, Schlitt HJ, Bleck JS, Schiebel HM, Kownatzki R, Maurer G, Strohmeyer SS, Schottmann R, Wonigeit K, Pichlmayr R, et al. (1988) Measurement of cyclosporine and 18 metabolites in blood, bile and urine by high-performance liquid chromatography. Transplant Proc 20:609-613.
23. Christians U, Strohmeyer S, Kownatzki R, Schiebel HM, Bleck J, Greipel J, Kohlhaw K, Schottmann R, and Sewing KF (1991) Investigations on the metabolic pathways of cyclosporine: I. Excretion of eyelosporine and its metabolites in human bile-isolation of 12 new cyclosporine metabolites. Xenobiotica 21:1185-1198.
24. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther 84:121-131.
25. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
26. Drahushuk AT, McGarrigle BP, Larsen KE, Stegeman JJ, and Olson JR (1998) Detection of CYP1A 1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. Carcinogenesis 19:1361-1368.
27. Drewe J, Ball HA, Beglinger C, Peng B, Kemmler A, Schachinger H, and Haefeli WE (2000) Effect of P-glycoprotein modulation on the clinical phamacokineties and adverse effects of morphine. Br J Clin Pharmacol 50:237-246.
28. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, and Lake BG (2003) Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31:282-288.
29. Einolf HJ, Bedi-Singh S, and Fischer V (2002) Precision-cut human liver slices as a model to examine changes in cytochrome P450 expression to predict or preclude potential drug-drug interactions. The Toxicologist 46:19.
30. Fee JP, Collier PS, Howard PJ, and Dundee JW (1987) Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 41:80-84.
31. Frye RF, Matzke GR, Adedoyin A, Porter JA, and Branch RA (1997) Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62:365-376.
32. Fuhr U (2000) Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 38:493-504.
33. Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, Foster BC, and Cameron DW (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 48:168-179.
34. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242-251.
35. Glockner R, Steinmetzer P, Drobner C, and Muller D (1999) Use of fresh and cryopreserved human liver slices in toxicology with special reference to in vitro induction of cytochrome P450. Toxicol In Vitro 13:531-535.
36. Goodwin B, Moore LB, Stoltz CM, McKee DD, and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427-431.
37. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
38. Gorski JC, Liu Y, Hall SD, and Haehner-Daniels BD (1999) The effect of clarithromycin on human cytochrome P450 (CYP) enzymes. Clin Pharmacol Ther 65:136.
39. Hamman MA, Bruce MA, Haehner-Danniels BD, and Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121.
40. Hase I, Oda Y, Tanaka K, Mizutani K, Nakamoto T, and Asada A (1997) I. v. fentanyl deereases the clearance of midazolam. Br J Anaesth 79:740-743.
41. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
42. Kaneko A, Lum JK, Yaviong L, Takahashi N, Ishizaki T, Benilsson L, Kobayakawa T, and Bjorkman A (1999) High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 9:581-590.
43. Kupferschmidt HH. Ha HR, Ziegler WH. Meier PJ, and Krahenbuhl S (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20-28.
44. Lake BG Ball SE, Renwick AB, Tredger JM, Kao J, Beamand JA, and Price RJ (1997) Induction of CYP3A isoforms in cultured precision-cut human liver slices. Xenobiotica 27:1165-1173.
45. Lake BG Charzat C, Tredger JM, Renwick AB, Beamand JA, and Price RJ (1996) Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica 26:297-306.
46. Lake BG Tredger JM, Renwick AB, Barton PT, and Price RJ (1998) 3,3′-Diindolylmethane induces CYPIA2 in cultured precision-cut human liver slices. Xenobiotica 28:803-811.
47. Lam Y, Ereshefsky L, Alfaro C, and Miller M (1999) In vivo inhibition of midazolam disposition by ketoconazole and fluoxetine and comparison to in vitro prediction. Clin Pharmacol Ther 65:143.
48. Lanchote VL, Ping WC, and Santos SR (1996) Influence of renal failure on cytochrome P450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine. Eur J Clin Pharmacol 50:83-89.
49. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
50. LeCluyse E. Madan A. Hamihon G, Carroll K. DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177- 188.
51. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, and Thummel KE (2001) In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781-791.
52. Linder MW, Prough RA, and Valdes R Jr (1997) Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43:254-266.
53. Liston HL, Markowitz JS, and DeVane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21:500-515.
54. Ludden LK, Ludden TM, Collins JM, Pentikis HS, and Strong JM (1997) Effect-of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. J Pharmacol Exp Ther 282:391-396.
55. Mackenzie PI, Miners JO, and McKinnon RA (2000) Polymorphisms in UDP glucuronosyl transferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 38:889-892.
56. Matsumoto S, Saito H, and Inui K (1994) Transcellular transport of oral cephalosporins in human intestinal epithelial cells, Caco-2: interaction with dipeptide transport systems in apical and basolateral membranes. J Pharmacol Exp Ther 270:498-504.
57. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
58. Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, and Fabre G (2000) Expression and induction of CYPIAI/IA2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 30:589-607.
59. Murray M (1997) Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 24:465-470.
60. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
61. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, and Kivisto KT (2001) Effects of rifampin on the pharmacokineties and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 69:400-406.
62. Olkkola KT, Arinko K, Luurila H, Hiller A, Saamivaara L, Himberg JJ, and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
63. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
64. Palmer JL, Scott RJ, Gibson A, Dickins M, and Pleasance S (2001) An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2El) and midazolam (CYP3A). Br J Clitz Pharmacol 52:555-561.
65. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
66. Prueksaritanont T, Vega JM, Rogers JD, Gagliano K, Greenberg HE, Gillen L, Brucker MJ, McLoughlin D, Wong PH, and Waldman SA (2000) Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 40:1274-1279.
67. Rao US and Scarborough GA (1994) Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 45:773-776.
68. Rege BD, Yu LX, Hussain AS, and Polli JE (2001) Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776-1786.
69. Ring BJ and Wrighton SA (2000) Industrial viewpoint: Application of in vitro drug metabolism in various phases of drug development, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD. and Eichelbaum M, eds) pp 29-39, Lippincott Williams & Wilkins, Philadelphia.
70. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed 2cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
71. Rogers JD, Zhao J, Liu L. Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson MF, Stepanavage M, and Vega JM (1999) Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 66:358-366.
72. Saulnier MJ and Vickers AE (2002) Optimization of organ slice longevity in culture to link gene expression with altered morphology. The Toxicologist 46:247.
73. Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, and Kirch W (1999) Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol talinolol in humans. Clin Pharmacol Ther 65:283-290.
74. Schwarz UI, Gramatte T, Krappweis J, Oertel R, and Kirch W (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167.
75. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
76. Stormer E, von Moltke LL, and Greenblatt DJ (2000) Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther 295:793-801.
77. Streetman DS. Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, and Bertino JS Jr (2000) Combined phenotypic assessment of CYP1A2, CYP2CI9, CYP2D6, CYP3A, N-acetyltransferase-2 and xanthine oxidase with the "Cooperstown cocktail" Clin. Pharmacol Ther 68:375-383.
78. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substmte-dependent modulation of CYP3A4 catalytic, activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
79. Taipalensuu J, Tomblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, and Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
80. Takahashi H and Echizen H (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40:587-603.
81. Tang W and Steams RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198.
82. Tang W, Steams RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
83. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, and Mikus G (2001) Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 70:405-414.
84. Tsunoda SM, Velez RL, and Greenblatt DJ (1999) Ketoconazole (K) inhibition of intestinal and hepatic cytochrome P450 3A4 (CYP3A4) activity using midazolam (M) as an in vivo probe. Clin Pharmacol Ther 65:172.
85. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080.
86. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
87. Veronese M, Gillen L. Dorval E, Hauck W, Waldman S, and Greenberg H (1999) Inhibition of hepatic and intestinal CYP3A4 by mibefradil measured by the erythromycin breath test (EBT) and oral midazolam pharmacokinetics (PK) (Abstract). Clin Pharmacol Ther 65:131.
88. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, and Siegmund W (2000a) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12.
89. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, et al. (2000b) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355.
90. Wong JY, Seah ES, and Lee EJ (2000) Pharmacogenetics: the molecular genetics of CYP2D6 dependent drug metabolism. Ann Acad Med Singapore 29:401-406.
91. Worboys PD and Cartile DJ (2001) Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica 31:539-556.
92. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
93. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, and Wood AJ (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539-549.
94. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, and Tokuda H (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204.
95. Yeates RA, Laufen H, and Zimmermann T (1996) Interaction between midazolam and clarithromycin: comparison with azithromycin, lnt J Clin Pharmacol Ther 34:400-405.
96. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, and Zhou HH (2001) Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 70:455-461.
97. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, and Wildfeuer A (1996) Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneim-Forsch 46:213-217.